welcome
Reuters

Reuters

Health

Health

Analysis-Pharma companies expected to absorb any tariff hit in short term

Reuters
Summary
Nutrition label

79% Informative

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines.

But in the near term the costs would likely be absorbed by drugmakers rather than patients.

The Trump administration has opened a national security investigation into pharmaceuticals.

The industry has been lobbying for phased-in tariffs.

VR Score

91

Informative language

99

Neutral language

34

Article tone

formal

Language

English

Language complexity

63

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.